One in two patients ‘safely quit’ T2DM meds after bariatric surgery
Findings 'bode well' for long-term diabetes remission, say Australian researchers.
Half of patients with morbid obesity and type 2 diabetes safely discontinue diabetes treatment within a year of bariatric surgery, Australian research suggests.
Among patients who still required insulin therapy after a year, the average daily dose was reduced by 73% — from 120 units to 32 units a day.
The researchers from Queensland Health and Griffith University said the findings confirmed the benefits of publicly funded bariatric surgery in the context of diabetes management.
Their longitudinal, prospective cohort study included 130 adults (mean age 52) referred to the Bariatric Surgery Initiative between 2017 to 2020.
